<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164775">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01859897</url>
  </required_header>
  <id_info>
    <org_study_id>okayama-1692</org_study_id>
    <nct_id>NCT01859897</nct_id>
  </id_info>
  <brief_title>A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan</brief_title>
  <acronym>CAVI-J</acronym>
  <official_title>A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAVI-J Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toho University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ehime University Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dokkyo Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Okayama University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Okayama University</source>
  <oversight_info>
    <authority>Japan:The ethics committee of Okayama University</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this five-year prospective observational follow-up study is to examine the
      additional benefits of using cardio-ankle vascular index (CAVI) as a predictive indicator of
      cardiovascular events in high-risk patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>major cardiac events</measure>
    <time_frame>five years</time_frame>
    <safety_issue>No</safety_issue>
    <description>cardiac death, nonfatal myocardial infarction, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>five years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>five years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Angina pectoris (with revascularization), New incidence of lower limb peripheral arterial disease(including lower limb arteriosclerosis obliterans), Aortic aneurysm, Aortic dissection, Heart failure that requires hospitalization, Deterioration in renal function (dialysis or renal transplantation)</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Stroke</condition>
  <condition>Cardiovascular Death</condition>
  <condition>Nonfatal Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Optimal therapy</arm_group_label>
    <description>All subjects will be treated by optimal medical therapy and lifestyle modification.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        primiary care clinic and hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients between 40 and 74 years of age who have either of the following:

          1. Type 2 diabetes mellitus

          2. Metabolic syndrome

          3. Grade I to III hypertension with the third layer of risk factors according to the
             guidelines for the management of hypertension japanese society of
             hypertension(JSH)2009

          4. Chronic kidney disease(stage G3a or G3b) according ot the clinical Practice Guidebook
             for Diagnosis and Treatment of Chronic Kidney Disease 2012 in Japan

          5. History of coronary artery disease or noncardiogenic cerebral infarction

        Exclusion Criteria:

          1. Under 40 years of age or over 74 years of age

          2. An ankle-brachial index less than 0.9

          3. Chronic atrial fibrillation

          4. Current symptoms of heart failure(NYHA class III or IV) or left ventricular
             dysfunction (EF below 40%)

          5. Malignancy

          6. Chronic kidney disease(G4 or G5)according ot the clinical Practice Guidebook for
             Diagnosis and Treatment of Chronic Kidney Disease 2012 in Japan

          7. chronic dialysis due to renal failure

          8. Taking steroids/immunosuppressants

          9. Hepatocirrhosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hajime Orimo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenkoin Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toru Miyoshi, MD</last_name>
    <phone>81-86-235-7351</phone>
    <email>miyoshit@cc.okayama-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Okayama University</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hiroshi Ito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.cavij.com/</url>
    <description>Click here for more information about this study (in Japanese)</description>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 5, 2013</lastchanged_date>
  <firstreceived_date>May 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Okayama University</investigator_affiliation>
    <investigator_full_name>CAVI-J Study Group</investigator_full_name>
    <investigator_title>CAVI-J study Group</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
